Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M948Revenue (TTM) $M36.6Net Margin (%)-677.6Altman Z-Score-3.9
Enterprise Value $M870EPS (TTM) $-6.4Operating Margin %-674.2Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-679.5Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio2.3Cash flow > EarningsN
Price/Sales25.25-y EBITDA Growth Rate %--Current Ratio2.3Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-118.8Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-1,200.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M39.1ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with CHRS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CHRSGeorge Soros 2016-03-31 Sold Out -0.05%$12.54 - $22.96
($16.44)
$ 24.2247%Sold Out0
CHRSGeorge Soros 2015-06-30 Buy 0.04%$21.07 - $30.58
($25.36)
$ 24.22-4%New holding127,600
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CHRS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CHRS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Watler Peter K.Chief Technical Officer 2016-07-20Sell73,741$25.02-3.2view
Watler Peter K.Chief Technical Officer 2016-07-11Sell43,495$20.0220.98view
Herman Alan C.Chief Scientific Officer 2016-07-01Sell4,250$16.8943.4view
Herman Alan C.Chief Scientific Officer 2016-06-01Sell4,250$18.6729.73view
Watler Peter K.Chief Technical Officer 2016-05-17Sell12,000$2021.1view
Watler Peter K.Chief Technical Officer 2016-05-02Sell21,493$26.89-9.93view
Herman Alan C.Chief Scientific Officer 2016-05-02Sell4,250$19.226.15view
Herman Alan C.Chief Scientific Officer 2016-04-01Sell4,250$21.3613.39view
Herman Alan C.Chief Scientific Officer 2016-02-05Sell2,000$15.0261.25view
Herman Alan C.Chief Scientific Officer 2015-12-01Sell11,333$29.49-17.87view

Quarterly/Annual Reports about CHRS:

News about CHRS:

Articles On GuruFocus.com
A Look at Pharma Company Dermira's Performance Mar 27 2015 

More From Other Websites
These new drugs might never get a chance to save the U.S. $250 billion Jul 20 2016
Why Amgen’s positive biosimilar news isn’t as good as it seems Jul 13 2016
New Reports on Recent Market Movers BioLife, Coherus, GoPro and Lannett Company Jul 13 2016
Coherus Biosciences Inc (CHRS) Is Looking To Compete With Amgen, Inc. (AMGN)’s Cancer Blockbuster Jul 12 2016
Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : July... Jul 12 2016
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 11 2016
Why Coherus Biosciences, Hortonworks and 3 Other Stocks Are Posting Big Gains Today Jul 11 2016
Coherus Announces Positive Topline Results for CHS-1701 (Pegfilgrastim Biosimilar Candidate)... Jul 11 2016
Coherus Announces Positive Topline Results for CHS-1701 (Pegfilgrastim Biosimilar Candidate)... Jul 11 2016
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 28 2016
Coherus Announces Positive Phase 2b Efficacy Data on Novel Oral Therapy in Relapsing Remitting... Jun 28 2016
Coherus Announces Positive Phase 2b Efficacy Data on Novel Oral Therapy in Relapsing Remitting... Jun 28 2016
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 14 2016
Coherus BioSciences Provides Update on IPRs Jun 13 2016
Coherus BioSciences Provides Update on IPRs Jun 13 2016
Coherus Presents Study Results Demonstrating Equivalence of its CHS-0214 Biosimilar to Etanercept Jun 10 2016
Coherus Presents Study Results Demonstrating Equivalence of its CHS-0214 Biosimilar to Etanercept Jun 10 2016
COHERUS BIOSCIENCES, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Other... Jun 03 2016
Coherus BioSciences to Present at Jefferies 2016 Healthcare Conference on June 8 Jun 03 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)